

USSN: 10/526,731
Attorney Docket: 2002.017 US
Response to Office Action of February 20, 2009

Amendments to the Claims:

Claims 1-20 (Canceled).

21. (Currently amended): Attenuated live parasite of the phylum Apicomplexa or the family of Trypanosomatidae capable of infecting cells, wherein ~~said parasite comprises~~ a ribosomal protein gene of said parasite is under the control of an inducible promoter, by which the promoter can be switched on and off, regulating the expression of the ribosomal protein gene, whereby ribosome synthesis is limited, thereby limiting parasite replication in infected cells.

22. (Previously presented): The attenuated live parasite according to Claim 21, wherein said parasite belongs to the Coccidia, the Piroplasmida or the Haemosporida.

23. (Previously presented): The attenuated live parasite according to Claim 22, wherein said parasite belongs to the family of the Eimeridiidae, Cryptosporidiidae or Sarcocystidae.

24. (Previously presented): The attenuated live parasite according to Claim 23, wherein said parasite belongs to the genus Eimeria, Cryptosporidium, Toxoplasma, Sarcocystis or Neospora.

25. (Previously presented): The attenuated live parasite according to Claim 22, wherein said parasite belongs to the family of the Babesiidae or the Theileriidae.

USSN: 10/526,731

Attorney Docket: 2002.017 US

Response to Office Action of February 20, 2009

26. (Previously presented): The attenuated live parasite according to Claim 25, wherein said parasite belongs to the genus Babesia or Theileria.

27. (Previously presented): The attenuated live parasite according to Claim 22, wherein said parasite belongs to the genus Plasmodium.

28. (Previously presented): The attenuated live parasite according to Claim 21, wherein said parasite belongs to the genus Trypanosoma or the genus Leishmania

29. (Previously presented): The attenuated live parasite according to Claim 21, wherein said inducible promoter is based upon an operator site and a repressor protein capable of reversibly binding said operator site.

30. (Previously presented): The attenuated live parasite according to Claim 21, wherein said inducible promoter is inducible by antibiotics.

31. (Previously presented): The attenuated live parasite according to claim 20, wherein said inducible promoter is inducible by tetracycline or anhydrotetracyclin, or a derivative thereof.

32. (Previously presented): The attenuated live parasite according to claim 21, wherein a tetR-

USSN: 10/526,731

Attorney Docket: 2002.017 US

Response to Office Action of February 20, 2009

system is used as the inducible promoter.

33. (Previously presented): The attenuated live parasite according to Claim 21, wherein said ribosomal protein gene is the gene encoding L9, S3, plastid-S9 or S13 of *Toxoplasma gondii*.

34. (Previously presented): An immunogenic composition comprising the attenuated live parasite of Claim 21 and a pharmaceutically acceptable carrier.

35. (Previously presented): A method for the production of an immunogenic composition, said method comprising the mixing of the live attenuated parasite according to Claim 21 and a pharmaceutically acceptable carrier.

Claims 36–38 (Canceled).